Skip to Main Content

Paper Details

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer.
Ann Oncol
112
2022
BRCA1, BRCA1/2, BRCA2, DDFS, EBC, IDFS, acute myeloid leukemia, breast cancer, cancers, early breast cancer, gBRCA1/2pv, germline, human, human epidermal growth factor receptor, myelodysplastic syndrome, olaparib, patients, poly(adenosine diphosphate-ribose), poly(adenosine diphosphate-ribose) polymerase
Author NameAffiliation
Judy E GarberDana-Farber Cancer Institute, Harvard Medical School
Susan M DomchekBasser Center for BRCA at the Abramson Cancer Center, University of Pennsylvania
James M FordStanford University School of Medicine
Sunil R LakhaniThe University of Queensland Centre for Clinical Research and Pathology Queensland
Sunil R LakhaniThe University of Queensland Centre for Clinical Research and Pathology Queensland
Barbro LinderholmSahlgrenska University Hospital, The Institute of Clinical Sciences, Gothenburg University
Larissa A KordeClinical Investigations Branch, The National Cancer Institute
Gabriele ZoppoliGruppo Oncologico Italiano di Ricerca Clinica, Parma Universita degli Studi di Genova and IRCCS Ospedale Policlinico San Martino
Gabriele ZoppoliGruppo Oncologico Italiano di Ricerca Clinica, Parma Universita degli Studi di Genova and IRCCS Ospedale Policlinico San Martino
  • 1 - 9

Datasets

Release 1.2